Despite their origin as incretin-based therapies for type 2 diabetes and obesity, several GLP-1 analogues have demonstrated CNS effects that suggest, either directly or indirectly, interaction with brain targets. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.